Publicacións nas que colabora con Alfredo José Lucendo Villarín (35)

2024

  1. Determinant factors for first-line treatment choice and effectiveness in pediatric eosinophilic esophagitis: an analysis of the EUREOS EoE CONNECT registry

    European Journal of Pediatrics, Vol. 183, Núm. 8, pp. 3567-3578

  2. Diagnosis of eosinophilic gastrointestinal disorders beyond eosinophilic esophagitis in adults. A brief review

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 8, pp. 901-905

  3. Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry

    Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264

  4. Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 5, pp. 604-612

  5. Psoriasis induced by antiTNF therapy in inflammatory bowel disease: Therapeutic management and evolution of both diseases in a nationwide cohort study

    Digestive and Liver Disease, Vol. 56, Núm. 12, pp. 2060-2068

  6. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  7. Sex-related differences in the presentation, management and response to treatment of eosinophilic esophagitis: Cross sectional analysis of EoE CONNECT registry

    United European Gastroenterology Journal

  8. Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA

    Pharmaceutics, Vol. 16, Núm. 5

2023

  1. Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on Helicobacter pylori Management (Hp-EuReg)

    Gut, Vol. 72, Núm. 11, pp. 2031-2037

  2. Corrigendum to “Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry” [Digestive and Liver Disease Volume 55, Issue 3, March 2023, Pages 350–359] (Digestive and Liver Disease (2023) 55(3) (350–359), (S1590865822007289), (10.1016/j.dld.2022.09.020))

    Digestive and Liver Disease

  3. Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry

    Digestive and Liver Disease, Vol. 55, Núm. 3, pp. 350-359

  4. Helicobacter pylori Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Helicobacter pylori Management

    Journal of Clinical Medicine, Vol. 12, Núm. 13

  5. Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated with Internal Fistulizing Disease: BIOSCOPE Study from GETECCU

    American Journal of Gastroenterology, Vol. 118, Núm. 6, pp. 1036-1046

  6. The Risk of Developing Disabling Crohn's Disease: Validation of a Clinical Prediction Rule to Improve Treatment Decision Making

    Digestive Diseases, Vol. 41, Núm. 6, pp. 879-889

2022

  1. Accurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe. An analysis of the EoE CONNECT Registry

    United European Gastroenterology Journal, Vol. 10, Núm. 5, pp. 507-517

  2. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  3. EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe

    Therapeutic Advances in Gastroenterology, Vol. 15

  4. Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients

    Frontiers in Medicine, Vol. 9

  5. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  6. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24